142 related articles for article (PubMed ID: 22772164)
1. Methods for the analysis of histone H3 and H4 acetylation in blood.
Rigby L; Muscat A; Ashley D; Algar E
Epigenetics; 2012 Aug; 7(8):875-82. PubMed ID: 22772164
[TBL] [Abstract][Full Text] [Related]
2. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
3. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
[TBL] [Abstract][Full Text] [Related]
5. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
6. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B
Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981
[TBL] [Abstract][Full Text] [Related]
7. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Pettazzoni P; Pizzimenti S; Toaldo C; Sotomayor P; Tagliavacca L; Liu S; Wang D; Minelli R; Ellis L; Atadja P; Ciamporcero E; Dianzani MU; Barrera G; Pili R
Free Radic Biol Med; 2011 Jan; 50(2):313-22. PubMed ID: 21078383
[TBL] [Abstract][Full Text] [Related]
8. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
10. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
11. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
13. Establishment and application of a flow cytometry-based method for detecting histone acetylation levels.
Li JH; Wang CF; Bai F; Zhuang Y; Mao ZJ; Sun YT
Yi Chuan; 2016 Jun; 38(6):581-587. PubMed ID: 27655319
[TBL] [Abstract][Full Text] [Related]
14. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
15. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells.
Uitrakul S; Hutton C; Veal GJ; Jamieson D
Eur J Clin Invest; 2019 Jul; 49(7):e13115. PubMed ID: 30929275
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
Zhang L; Ma YP; Jia G; Lu YJ; Zhang L; Lu H; Chang MX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1122-6. PubMed ID: 23114131
[TBL] [Abstract][Full Text] [Related]
17. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.
Iancu-Rubin C; Gajzer D; Mosoyan G; Feller F; Mascarenhas J; Hoffman R
Exp Hematol; 2012 Jul; 40(7):564-74. PubMed ID: 22381681
[TBL] [Abstract][Full Text] [Related]
19. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
